Vivani Medical narrows second quarter 2026 loss to $6.4M as NPM-139 clinical trial dosing completes

Vivani Medical reported a net loss of $6.4 million for the second quarter of 2026, a slight improvement from the $7.1 million loss in the same period last year. As a clinical-stage biopharmaceutical company, Vivani reported no revenue while ending the period with $20.8 million in cash to support its long-acting implant pipeline.

Key Highlights

• Successfully dosed all 20 participants in the SLIM-1 Phase 1 trial for lead asset NPM-139, with top-line safety and pharmacokinetic data expected in November 2026.
• Entered a non-exclusive agreement with Novo Nordisk to evaluate the proprietary NanoPortal technology and the NPM-139 semaglutide implant.
• Progressed the definitive merger agreement for subsidiary Cortigent, expected to list on the Nasdaq as a standalone company (CRGT) in the third quarter of 2026.